Monthly Archives: January 2020

Breaking News for GIST Patients – Avapritinib Approved!

Blueprint Medicines announced that the FDA has approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.

By |2020-01-10T16:06:14-05:00January 9th, 2020|News|
Go to Top